Vivo studies of Scn5a+/-mice modeling brugada syndrome demonstrate both conduction and repolarization abnormalities

Journal of Electrocardiology

Volumn 43, Issue 5, 2010, Pages 433-439

  Martin, Claire A ^a   Zhang, Yanmin ^a,b   Grace, Andrew A ^a   Huang, Christopher L H ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FLECAINIDE; QUINIDINE; ANTIARRHYTHMIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARRHYTHMOGENESIS; ARTICLE; BRUGADA SYNDROME; CONTROLLED STUDY; ELECTROCARDIOGRAPHY; HEART CONDUCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; QT DISPERSION; ST SEGMENT ELEVATION; ANIMAL; DISEASE MODEL; HEART MUSCLE CONDUCTION SYSTEM; MOUSE STRAIN; PATHOPHYSIOLOGY; PHENOTYPE;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; BRUGADA SYNDROME; DISEASE MODELS, ANIMAL; ELECTROCARDIOGRAPHY; FLECAINIDE; HEART CONDUCTION SYSTEM; MICE; MICE, INBRED STRAINS; PHENOTYPE; QUINIDINE;

EID: 79551476266     PISSN: 00220736     EISSN: 15328430     Source Type: Journal    
DOI: 10.1016/j.jelectrocard.2010.05.015     Document Type: Article

References (25)

1. Meregalli PG, Wilde AA, Tan HL. Pathophysiological mechanisms of Brugada syndrome: Depolarization disorder, repolarization disorder, or more? Cardiovasc Res 2005;67:367.
2. Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation 1999;100:1660.
3. Brugada R, Brugada J, Antzelevitch C, et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation 2000; 101:510.
4. Alings M, Dekker L, Sadee A, et al. Quinidine induced electrocardiographic normalization in two patients with Brugada syndrome. Pacing Clin Electrophysiol 2001;24(9 Pt 1):1420.
5. Papadatos GA, Wallerstein PM, Head CE, et al. Slowed conduction and ventricular tachycardia after targeted disruption of the cardiac sodium channel gene Scn5a. Proc Natl Acad Sci U S A 2002;99:6210.
6. Martin CA, Zhang Y, Grace AA, et al. Increased right ventricular repolarization gradients promote arrhythmogenesis in a murine model of Brugada syndrome. J Cardiovasc Electrophysiol 2010:1. doi:10.1111/ j.1540-8167.2010. 01767.x [Electronic publication ahead of print].
7. Butrous G. The QT interval and other representation of ventricular repolarization. Curr Opin Cardiol 1987;2:43.
8. Mitchell GF, Jeron A, Koren G. Measurement of heart rate and Q-T interval in the conscious mouse. Am J Physiol 1998;274(3 Pt 2):H747.
9. Remme CA, Verkerk AO, Nuyens D, et al. Overlap syndrome of cardiac sodium channel disease in mice carrying the equivalent mutation of human SCN5A-1795insD. Circulation 2006;114:2584.
10. Berul CI, Aronovitz MJ, Wang PJ, et al. In vivo cardiac electrophysiology studies in the mouse. Circulation 1996;94:2641.
11. Danik S, Cabo C, Chiello C, et al. Correlation of repolarization of ventricular monophasic action potential with ECG in the murine heart. Am J Physiol Heart Circ Physiol 2002;283:H372.
12. Jaccard J, Wan CK. LISREL approaches to interaction effects in mulitple regression. Thousand Oaks (CA): Sage Publications; 1996.
13. Fish JM, Antzelevitch C. Role of sodium and calcium channel block in unmasking the Brugada syndrome. Heart Rhythm 2004;1:210.
14. Nakamura W, Segawa K, Ito H, et al. Class IC antiarrhythmic drugs, flecainide and pilsicainide, produce ST segment elevation simulating inferior myocardial ischemia. J Cardiovasc Electrophysiol 1998;9:855.
15. Watanabe H, Chinushi M, Washizuka T, et al. Variable electrocardiographic effects of short-term quinidine sulfate administration in Brugada syndrome. Pacing Clin Electrophysiol 2005;28:372.
16. Li RA, Leppo M, Miki T, et al. Molecular basis of electrocardiographic ST-segment elevation. Circ Res 2000;87:837.
17. Shimizu W, Antzelevitch C, Suyama K, et al. Effect of sodium channel blockers on ST segment,QRSduration, and correctedQTinterval in patients with Brugada syndrome. J Cardiovasc Electrophysiol 2000;11:1320.
18. Tukkie R, Sogaard P, Vleugels J, et al. Delay in right ventricular activation contributes to Brugada syndrome. Circulation 2004;109:1272.
19. Makiyama T, Akao M, Tsuji K, et al. High risk for bradyarrhythmic complications in patients with Brugada syndrome caused by SCN5A gene mutations. J Am Coll Cardiol 2005;46:2100.
20. Pitzalis MV, Anaclerio M, Iacoviello M, et al. QT-interval prolongation in right precordial leads: An additional electrocardiographic hallmark of Brugada syndrome. J Am Coll Cardiol 2003;42:1632.
21. Viskin S, Wilde AA, Tan HL, et al. Empiric quinidine therapy for asymptomatic Brugada syndrome: Time for a prospective registry. Heart Rhythm 2009;6:401.
22. Alings M, Wilde A. "Brugada" syndrome: Clinical data and suggested pathophysiological mechanism. Circulation 1999;99:666.
23. Burnes JE, Ghanem RN, Waldo AL, et al. Imaging dispersion of myocardial repolarization, I: Comparison of body-surface and epicardial measures. Circulation 2001;104:1299.
24. Ikeda T, Sakurada H, Sakabe K, et al. Assessment of noninvasive markers in identifying patients at risk in the Brugada syndrome: Insight into risk stratification. J Am Coll Cardiol 2001;37:1628.
25. Fauchier L, Pierre B, Robin I, et al. 13. Brugada syndrome, LQTS, and ARVC: 13.5 abnormal QT dynamics and nocturnal temporal QT dispersion in Brugada syndrome. Europace 2005;7:S21.